Participated · Series C · Jun 2026

Flare Therapeutics is a clinical-stage biotech headquartered in Cambridge, Mass., that focuses exclusively on drugging transcription factors using an integrated discovery platform to identify ligands to previously undrugged proteins. The company has prioritized FX-111, a first-in-class degrader targeting ARON for prostate cancer, which received IND clearance and is expected to enter clinical development in Q3 2026. FlareTx is also advancing an ARON RIPTAC program through preclinical development to complement FX-111 and expand its ability to address AR-driven prostate cancer. Separately, FX-909, an oral PPARG inhibitor targeting luminal lineage biology in urothelial cancer, is in a Phase 1B dose expansion and the company intends to progress it via an external partnership. The recent $85M Series C provides capital to advance these programs, support working capital and general corporate purposes. The company appointed Anna Protopapas as CEO concurrent with the financing to guide its next phase of clinical and corporate development.

Led · Series B · Jun 2026

Oblenio Bio is advancing LBL-051, a tri-specific T-cell engager that unites BCMA, CD19 and CD3 and is specifically engineered for autoimmune patients. Preclinical data presented at EULAR 2026 showed complete depletion of peripheral and tissue B cells and plasma cells with step-up dosing, emergence of immature non-memory B cells upon recovery, dose-dependent decreases in peripheral immunoglobulins, and no observed cytokine release syndrome in non-human primates. The company is moving rapidly toward clinical development and plans to initiate a first-in-human proof-of-concept study this year. Oblenio holds an exclusive option from Leads Biolabs for a global license to develop, manufacture, and commercialize LBL-051. Its leadership team includes CEO Samantha Truex, and the board will include representatives from Pfizer Ventures, Deep Track Capital, and Aditum Bio following the Series B. Oblenio is based in Cambridge, Mass., and has just completed a $62 million Series B to fund its clinical program.

Participated · Series B · Jun 2026

COUR Pharma develops first-in-class antigen-specific immune tolerance therapies using a proprietary nanoparticle platform that encapsulates disease-relevant antigens to reprogram autoimmune responses. Its lead program, CNP-103, encapsulates four recombinant proteins and is designed to induce tolerance to antigens driving type 1 diabetes; it is currently in a Phase 2 randomized, double-blind, placebo-controlled trial (NCT06783309) in recently diagnosed adolescents and adults. COUR says the proteins in CNP-103 are believed to cover over 95% of known T1D-driving antigens and aims to prevent further islet cell destruction and preserve insulin production. The company is pursuing partnerships to advance CNP-104 for primary biliary cholangitis and CNP-106 for myasthenia gravis. COUR recently raised $50 million in a Series B to support the clinical advancement of CNP-103, with participation from strategic and venture investors including Lumira Ventures, Roche Venture Fund, and Sanofi.

Participated · Series C · Apr 2026

STORM Therapeutics is a clinical-stage biotech headquartered in Cambridge, UK, led by CEO Jerry McMahon. Its lead candidate, STC-15, is an oral small-molecule inhibitor of METTL3 and is described as the first RNA‑modifying enzyme inhibitor to enter human clinical trials. STC-15 is currently being assessed as a monotherapy in a Phase 2 study for selected sarcoma indications, and the company has reported dosing the first patient in that study. In April 2026 STORM raised $56M in a Series C to support advancement of STC-15 and to enhance the Phase 2 program. The company’s core focus is developing therapies that target RNA modifications to reprogram malignant cells.

Participated · Series B · Mar 2026

Crossbow Therapeutics is developing a portfolio of T-Bolt™ T-cell engager (TCE) therapies built from T-cell receptor-mimetic antibodies that target peptide–HLA (pHLA) complexes on cancer cells. Its lead program, CBX-250, is a first-in-class TCE targeting a pHLA specific to myeloid cancer cells and is being evaluated in the ongoing CROSSCHECK-001 Phase 1 trial in relapsed and refractory myeloid malignancies. The company is advancing CBX-663, a TCE targeting a TERT-derived pHLA, toward IND submission and a planned Phase 1 start in Q3 2026 for multiple hematologic and solid tumors. Crossbow positions its T-Bolt™ platform as broadly adaptable to address intracellular cancer targets previously unreachable by antibodies. The company will present preclinical data for both programs at the AACR 2026 Annual Meeting and expects initial clinical data from CBX-250 around the end of 2026. The recent $77 million Series B is intended to fund completion of CBX-250’s Phase 1 and to accelerate initiation and development of additional T-Bolt™ programs.